What is the current stock price of Calliditas Therapeutics AB (publ) (CALT)?

As of the latest market data, Calliditas Therapeutics AB (publ) (CALT) is trading at $40.00. The stock has seen a loss of -0.10% today.

Does Calliditas Therapeutics AB (publ) (CALT) pay a dividend?

Based on current data, Calliditas Therapeutics AB (publ) does not have a confirmed active dividend policy.

What is the market cap of Calliditas Therapeutics AB (publ)?

The current market capitalization of Calliditas Therapeutics AB (publ) (CALT) is approximately unavailable.

CALT

Calliditas Therapeutics AB (publ)·Healthcare

40.00

0.100%(−0.04)

Market Closed

60.85

52.125%(+20.85)

After Hours

Last Updated: — ET

52W L: $15.2552W H: $43.00

CALT NEWS

defenseworld.net

Mar 10

Financial Survey: MindWalk (NASDAQ:HYFT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

MindWalk (NASDAQ: HYFT - Get Free Report) and Calliditas Therapeutics AB (publ) (NASDAQ: CALT - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Risk and Volatility MindWalk has a

defenseworld.net

Feb 7

Analyzing Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

Calliditas Therapeutics AB (publ) (NASDAQ: CALT - Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation. Insider and Institutional Ownership 2.8%

defenseworld.net

Jan 26

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & Palatin Technologies (PINK:PTNT) Critical Analysis

Calliditas Therapeutics AB (publ) (NASDAQ: CALT - Get Free Report) and Palatin Technologies (PINK: PTNT - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends. Volatility and Risk Calliditas Therapeutics

Company Profile

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Sector

Healthcare

Industry

Biotechnology

Employees

222

IPO Date

2020-06-05

Beta

1.46

Websitewww.calliditas.se↗